Dexilant Solutab Patent Expiration

Dexilant Solutab is a drug owned by Takeda Pharmaceuticals Usa Inc. It is protected by 28 US drug patents filed in 2016. Out of these, 7 drug patents are active and 21 have expired. Based on its patents and exclusivities, its generic launch date is estimated to be Mar 10, 2029. Details of Dexilant Solutab's patents and their expiration are given in the table below.


Drug Patent Number Drug Patent Title Drug Patent Expiry Status
These drug patents protects the active chemical substance. Only drug patent owner can launch products that use this active substance.
US9145389 Benzimidazole compound crystal
Jun, 2020

(4 years ago)

Expired
US7285668 Process for the crystallization of (R)- or (S)-lansoprazole
Jun, 2020

(4 years ago)

Expired
US6462058 Benzimidazole compound crystal
Jun, 2020

(4 years ago)

Expired
US6664276 Benzimidazole compound crystal
Jan, 2023

(1 year, 5 months ago)

Expired
These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc).
US7399485 Rapidly Disintegrable solid preparation
May, 2018

(6 years ago)

Expired
US7399485

(Pediatric)

Rapidly Disintegrable solid preparation
Nov, 2018

(5 years ago)

Expired
US7875292 Orally disintegrable tablets
May, 2019

(5 years ago)

Expired
US6238994 Method of creating a rough electrode (high surface area) from Ti and TiN and resulting article
May, 2019

(5 years ago)

Expired
US7431942 Orally disintegrable tablets
May, 2019

(5 years ago)

Expired
US6328994 Orally disintegrable tablets
May, 2019

(5 years ago)

Expired
US6328994

(Pediatric)

Orally disintegrable tablets
Nov, 2019

(4 years ago)

Expired
US6238994

(Pediatric)

Method of creating a rough electrode (high surface area) from Ti and TiN and resulting article
Nov, 2019

(4 years ago)

Expired
US7875292

(Pediatric)

Orally disintegrable tablets
Nov, 2019

(4 years ago)

Expired
US7431942

(Pediatric)

Orally disintegrable tablets
Nov, 2019

(4 years ago)

Expired
US6939971 Benzimidazole compound crystal
Jun, 2020

(4 years ago)

Expired
US7285668

(Pediatric)

Process for the crystallization of (R)- or (S)-lansoprazole
Dec, 2020

(3 years ago)

Expired
US6939971

(Pediatric)

Benzimidazole compound crystal
Dec, 2020

(3 years ago)

Expired
US6462058

(Pediatric)

Benzimidazole compound crystal
Dec, 2020

(3 years ago)

Expired
US6664276

(Pediatric)

Benzimidazole compound crystal
Jul, 2023

(11 months ago)

Expired
US8784885 Controlled release preparation
Oct, 2023

(9 months ago)

Expired
US8784885

(Pediatric)

Controlled release preparation
Apr, 2024

(3 months ago)

Expired
US9238029 Multiple PPI dosage form
Jan, 2026

(1 year, 5 months from now)

Active
US8461187 Multiple PPI dosage form
Jan, 2026

(1 year, 5 months from now)

Active
US9011926 Method for producing granules
Feb, 2026

(1 year, 7 months from now)

Active
US8461187

(Pediatric)

Multiple PPI dosage form
Jul, 2026

(1 year, 11 months from now)

Active
US8871273 Method for producing granules
Jan, 2028

(3 years from now)

Active
US8871273

(Pediatric)

Method for producing granules
Jul, 2028

(3 years from now)

Active
US9241910 Orally-disintegrating solid preparation
Mar, 2029

(4 years from now)

Active

Stay ahead of others in designing the generic launch strategy of these 5 blockbuster drugs expiring in next 5 years.

Get the exclusive patent insights now. Don't be the last to know.

Several oppositions have been filed on Dexilant Solutab's European patents. EP oppositions can significantly impact the timeline for the generic launch of drugs. If an opposition results in the revocation or amendment of a patent, it can shorten the exclusivity period of the original drug. This can lead to an earlier entry of generic versions into the market. To help you estimate the potential early arrival of Dexilant Solutab's generic, the next section provides detailed information on ongoing and past EP oppositions related to Dexilant Solutab patents.

Dexilant Solutab's oppositions filed in EPO

Dexilant Solutab has faced multiple oppositions in the European Patent Office. The earliest opposition was filed on Jan 02, 2009, by Teva Pharmaceutical Industries Ltd.. This opposition was filed on patent number EP00937235A. Click below to reveal the latest opposition data.


Application Filing Date Opposition Party Legal Status
Patent litigations
EP10175046A Jun, 2016 Aechter, Bernd Patent maintained as amended
EP03754116A Dec, 2013 Sanovel IIaƧ San. ve Tic. A.S. Patent maintained as amended
EP00937235A Jan, 2009 Teva Pharmaceutical Industries Ltd. Opposition procedure closed


US patents provide insights into the exclusivity only within the United States, but Dexilant Solutab is protected by patents in multiple countries. Understanding the full scope of patent protection is crucial in strategizing market entry. By looking at the broader patent landscape, you can identify markets with weaker patent protection which could be ideal generic entry points. The following section offers details on Dexilant Solutab's family patents as well as insights into ongoing legal events on those patents.

Dexilant Solutab's family patents

Dexilant Solutab has patent protection in a total of 41 countries. It's US patent count contributes only to 17.4% of its total global patent coverage. 10 countries have all of their patents expired or invalidated which has opened up potential generic launch opportunities in these countries. Click below to unlock the full patent family tree for Dexilant Solutab.

Family Patents

Coming Soon

Patent Strength Analyzer

Will this be useful for you?

YesNo

Thank you for your response šŸ„³



Generic Launch

Generic Release Date:

Dexilant Solutab's generic launch date based on the expiry of its last outstanding patent is estimated to be Mar 10, 2029 (This date is subject to change depending upon the patent filing activities by the drug owner or exclusivity additions to its drug application)

Dexilant Solutab Generics:

Dexlansoprazole is the generic name for the brand Dexilant Solutab. 3 different companies have already filed for the generic of Dexilant Solutab, with Endo Operations having the maximum number of approved applications. Check out the entire list of companies who have already received approval for Dexilant Solutab's generic





About Dexilant Solutab

Dexilant Solutab is a drug owned by Takeda Pharmaceuticals Usa Inc. It is used for treating gastroesophageal reflux disease (GERD) and maintaining the healing of erosive esophagitis. Dexilant Solutab uses Dexlansoprazole as an active ingredient. Dexilant Solutab was launched by Takeda Pharms Usa in 2016.

Market Authorisation Date:

Dexilant Solutab was approved by FDA for market use on 26 January, 2016.

Active Ingredient:

Dexilant Solutab uses Dexlansoprazole as the active ingredient. Check out other Drugs and Companies using Dexlansoprazole ingredient

Treatment:

Dexilant Solutab is used for treating gastroesophageal reflux disease (GERD) and maintaining the healing of erosive esophagitis.

Dosage:

Dexilant Solutab is available in tablet, orally disintegrating, delayed release form for oral use. Given below is detailed information on Dosage -

Strength Dosage Form Availability Application Pathway
30MG TABLET, ORALLY DISINTEGRATING, DELAYED RELEASE Discontinued ORAL